3 recruiting, 2 completed, 1 not yet recruiting, 1 withdrawn. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 3, Completed 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Recruiting 3, Completed 1, Withdrawn 1 |
Follow SOC: new trials by email Literature Review of SOC trials Research Report on SOC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics Gepotidacin, SOC - Urinary Tract Infections | Phase 1 | Not yet recruiting | GlaxoSmithKline | 25 | 2026-09-18 | 2026-09-28 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| A Study of AZD0120 in Autoimmune Diseases AZD0120, SOC - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 27 | 2026-01-09 | 2026-11-02 |
| Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors GTAEXS617, SoC - Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 230 | 2023-07-06 | 2026-08-13 |
| Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics DSTA4637S, Placebo, SOC - Bacteremia | Phase 1 | Completed | Genentech, Inc. | 27 | 2017-07-13 | 2020-01-22 |
| Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery. D-PLEX, Open heart surgery - Postoperative Wound Infection Superficial Incisional, Postoperative Wound Infection Deep Incisional Surgical Site | Phase 1 / Phase 2 | Completed | PolyPid Ltd. | 81 | 2016-10-12 | 2026-04-13 |
| Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients Selinexor, Standard-of-Care, Vehicle Gel - Diabetic Foot Ulcers | Phase 1 / Phase 2 | Withdrawn | Karyopharm Therapeutics Inc | 2015-01-01 | 2023-01-20 |
Carcinoma, Non-Small-Cell Lung (2) · Triple Negative Breast Neoplasms (2) · Arthritis, Rheumatoid (1) · Bacteremia (1) · Bacterial Infections (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Diabetes Mellitus (1) · Diabetic Foot (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Foot Ulcer (1)
Arvinas Inc. (1) · AstraZeneca (1) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. (1) · Genentech, Inc. (1) · GlaxoSmithKline (1) · Karyopharm Therapeutics Inc (1) · PolyPid Ltd. (1)
United States (5) · Spain (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Germany (1) · Israel (1) · New Zealand (1) · South Korea (1) · Sweden (1)
2016 (1), 2025 (1)